Dig­i­tal ther­a­peu­tics 2023: Swing and tri­al part­ner Cu­rav­it kick off fi­bromyal­gia study

Af­ter the boom-and-bust cy­cling in dig­i­tal ther­a­peu­tics over the past few years, dig­i­tal health providers are look­ing for 2023 to be a sta­bi­liz­ing year. Two of those com­pa­nies are dig­i­tal ther­a­peu­tics de­vel­op­er Swing Ther­a­peu­tics and all-vir­tu­al CRO Cu­rav­it Clin­i­cal Re­search.

The pair are cur­rent­ly en­rolling a tri­al for Swing’s Stan­za, a pre­scrip­tion smart­phone DTx for fi­bromyal­gia. The cog­ni­tive be­hav­ioral ther­a­py treat­ment, which re­ceived a break­through de­vice des­ig­na­tion from the FDA in 2021, be­came avail­able for pa­tients in Sep­tem­ber, along­side the for­mal clin­i­cal tri­al which will fin­ish en­roll­ment soon with the study set to com­plete in the third quar­ter.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN